타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials | administered by PDS290 pen-injector (Semaglutide, Semaglutide (administered by PDS290 pen-injector)) Prof. Dr. Martin Wabitsch·Monogenic Obesity 1 trials | |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Semaglutide (administered by PDS290 pen-injector) |
Overview Company | Eli Lilly | Novo Nordisk | Prof. Dr. Martin Wabitsch |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | Monogenic Obesity |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Monogenic Obesity |
Overview Phase | APPROVED | APPROVED | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) | — |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. | GI intolerance leading to discontinuation; plateau after dose titration | — |
Positioning Development positioning | — | 1L–2L after metformin (T2D); chronic weight management | — |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. | — |
MoA Biomarker | HbA1c, body weight, lipids. | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. | — |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | — |
Toxicology Animal (cat.) | — | NHP | — |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
Preclinical Animal (cat.) | Mouse | Mouse | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials | administered by PDS290 pen-injector (Semaglutide, Semaglutide (administered by PDS290 pen-injector)) Prof. Dr. Martin Wabitsch·Monogenic Obesity 1 trials | |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Semaglutide (administered by PDS290 pen-injector) |
Overview Company | Eli Lilly | Novo Nordisk | Prof. Dr. Martin Wabitsch |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | Monogenic Obesity |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Monogenic Obesity |
Overview Phase | APPROVED | APPROVED | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) | — |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. | GI intolerance leading to discontinuation; plateau after dose titration | — |
Positioning Development positioning | — | 1L–2L after metformin (T2D); chronic weight management | — |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. | — |
MoA Biomarker | HbA1c, body weight, lipids. | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. | — |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | — |
Toxicology Animal (cat.) | — | NHP | — |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
Preclinical Animal (cat.) | Mouse | Mouse | — |
추천 비교
추천 비교